A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-Period Crossover Polysomnography Study to Evaluate Safety and Efficacy of MK4305 in Patients With Primary Insomnia.

Trial Profile

A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-Period Crossover Polysomnography Study to Evaluate Safety and Efficacy of MK4305 in Patients With Primary Insomnia.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Suvorexant (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 18 Mar 2014 The number of treatment arms changed from 4 to 8
    • 10 Jun 2010 Results presented at the 24th Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2010), and reported in a Merck media release.
    • 10 Jun 2010 Primary endpoint 'Sleep efficiency' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top